Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.…
Foghorn Therapeutics Inc. (FHTX) Q3 Earnings and Revenues Beat Estimates
Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
Foghorn Therapeutics (NASDAQ: FHTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 106 employees.
The shares were at 1.720 USD on 20 November 2026, down 60.6% over 52 weeks. Its 52-week range is 1.660 USD to 7.350 USD: the price is 76.6% below the high and 3.6% above the low.
At a market capitalisation of 103.14M USD, it trades at 19.1 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 42% for FHTX.
Foghorn Therapeutics reports return on equity of 68.5%, an operating margin of 8.0% and revenue up 924.7% year over year.
It holds more cash than debt, a net cash position of 112.35M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 4.167 USD is 142.2% above the current price. The next earnings report is expected on 11 March 2027.